GNPX saw its Momentum Indicator move below the 0 level on September 25, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 71 similar instances where the indicator turned negative. In 67 of the 71 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNPX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for GNPX entered a downward trend on September 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where GNPX advanced for three days, in 148 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
GNPX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.117) is normal, around the industry mean (2.835). P/E Ratio (0.061) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. GNPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The RSI Indicator for LONA moved out of oversold territory on October 01, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 33 of the 34 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on LONA as a result. In 75 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for LONA just turned positive on October 06, 2026. Looking at past instances where LONA's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
Following a +11.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where LONA advanced for three days, in 216 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
LONA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 55 cases where LONA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The 50-day moving average for LONA moved below the 200-day moving average on September 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LONA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for LONA entered a downward trend on October 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.458) is normal, around the industry mean (2.835). P/E Ratio (-0.226) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. LONA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LONA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
GNPX | LONA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 48 Fair valued | 61 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 97 | 64 | |
P/E GROWTH RATING 1..100 | 96 | 88 | |
SEASONALITY SCORE 1..100 | 24 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GNPX's Valuation (48) in the Pharmaceuticals Major industry is in the same range as LONA (61) in the null industry. This means that GNPX’s stock grew similarly to LONA’s over the last 12 months.
GNPX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as LONA (100) in the null industry. This means that GNPX’s stock grew similarly to LONA’s over the last 12 months.
GNPX's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as LONA (100) in the null industry. This means that GNPX’s stock grew similarly to LONA’s over the last 12 months.
LONA's Price Growth Rating (64) in the null industry is somewhat better than the same rating for GNPX (97) in the Pharmaceuticals Major industry. This means that LONA’s stock grew somewhat faster than GNPX’s over the last 12 months.
LONA's P/E Growth Rating (88) in the null industry is in the same range as GNPX (96) in the Pharmaceuticals Major industry. This means that LONA’s stock grew similarly to GNPX’s over the last 12 months.
| GNPX | LONA | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 73% | 4 days ago 90% |
| Stochastic ODDS (%) | 4 days ago 88% | 4 days ago 90% |
| Momentum ODDS (%) | 4 days ago 90% | 4 days ago 86% |
| MACD ODDS (%) | N/A | 4 days ago 83% |
| TrendWeek ODDS (%) | 4 days ago 90% | 4 days ago 85% |
| TrendMonth ODDS (%) | 4 days ago 90% | 4 days ago 84% |
| Advances ODDS (%) | 12 days ago 76% | 7 days ago 83% |
| Declines ODDS (%) | 4 days ago 90% | 4 days ago 85% |
| BollingerBands ODDS (%) | 4 days ago 77% | 4 days ago 87% |
| Aroon ODDS (%) | 4 days ago 90% | 4 days ago 82% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GNPX’s FA Score shows that 0 FA rating(s) are green while LONA’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GNPX’s TA Score shows that 4 TA indicator(s) are bullish while LONA’s TA Score has 5 bullish TA indicator(s).
GNPX (@Biotechnology) experienced а -22.43% price change this week, while LONA (@Biotechnology) price change was -9.57% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.77%. For the same industry, the average monthly price growth was -18.56%, and the average quarterly price growth was -19.45%.
LONA is expected to report earnings on Nov 05, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RJVI | 24.40 | 0.02 | +0.07% |
| RJ Eagle Vertical Income ETF (RJVI) | |||
| IBTR | 23.75 | 0.01 | +0.06% |
| iShares iBonds Dec 2036 Term Treasury ETF (IBTR) | |||
| BHFAL | 15.95 | N/A | N/A |
| Brighthouse Financial | |||
| MOO | 81.79 | -0.35 | -0.43% |
| VanEck Agribusiness ETF (MOO) | |||
| SMIZ | 40.66 | -0.58 | -1.41% |
| Zacks Small/Mid Cap ETF (SMIZ) | |||
A.I.dvisor indicates that over the last year, GNPX has been closely correlated with CANF. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if GNPX jumps, then CANF could also see price increases.
| Ticker / NAME | Correlation To GNPX | 1D Price Change % | ||
|---|---|---|---|---|
| GNPX | 100% | -7.86% | ||
| CANF - GNPX | 93% Closely correlated | -4.86% | ||
| APVO - GNPX | 86% Closely correlated | -4.71% | ||
| ICU - GNPX | 82% Closely correlated | -5.23% | ||
| MLEC - GNPX | 76% Closely correlated | -10.16% | ||
| LONA - GNPX | 76% Closely correlated | -1.70% | ||
More | ||||
A.I.dvisor indicates that over the last year, LONA has been closely correlated with CANF. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if LONA jumps, then CANF could also see price increases.
| Ticker / NAME | Correlation To LONA | 1D Price Change % | ||
|---|---|---|---|---|
| LONA | 100% | -1.70% | ||
| CANF - LONA | 77% Closely correlated | -4.86% | ||
| ICU - LONA | 76% Closely correlated | -5.23% | ||
| GNPX - LONA | 62% Loosely correlated | -7.86% | ||
| MLEC - LONA | 58% Loosely correlated | -10.16% | ||
| CNTN - LONA | 40% Loosely correlated | -9.36% | ||
More | ||||